An open-label study to characterize the pharmacokinetic parameters of erlotinib (Tarceva, OSI 774) in cancer patients with advanced solid tumors, with adequate and moderately impaired hepatic function.

Trial Profile

An open-label study to characterize the pharmacokinetic parameters of erlotinib (Tarceva, OSI 774) in cancer patients with advanced solid tumors, with adequate and moderately impaired hepatic function.

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Most Recent Events

    • 30 Jan 2011 Additional lead trial investigator (T R J Evans) identified as reported by United Kingdom Clinical Research Network.
    • 30 Jan 2011 New source identified and integrated (United Kingdom Clinical Research Network; 9781).
    • 15 Aug 2007 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top